Deutsche Bank Lifts Alcatel (ALU) to Buy, Says Market Discounting Too Much, Liquidity Intact
Tweet Send to a FriendGet Alerts ALU Hot Sheet
Price: $1.50 -0.66%
Rating Summary:
7 Buy, 8 Hold, 8 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 13
Rating Summary:
7 Buy, 8 Hold, 8 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 13
Trade ALU Now!
Alcatel-Lucent (NYSE: ALU) shares are moving higher Wednesday morning, following an upgrade at Deutsche Bank.
The firm now rates Alcatel a Buy, from it's previous rating of Hold. It maintains a price target of €2.
Deutsche said that markets are "discounting too harsh a financial distress scenario for the company." Deutsche gives 5 reasons for such a call:
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm now rates Alcatel a Buy, from it's previous rating of Hold. It maintains a price target of €2.
Deutsche said that markets are "discounting too harsh a financial distress scenario for the company." Deutsche gives 5 reasons for such a call:
- Our stress test indicates that even assuming a cumulative 17% network revenue decline (similar to 2009), ALU should maintain sufficient liquidity in 2012/13.
- The expected €1.1 billion inflow from Genesys sale proceeds in Q1 should provide a material liquidity boost.
- Additional cash contributions to the company’s US pension plans are likely not required in 2012.
- The company’s ~€900m in combined 2012 & 13 debt maturities could potentially be rolled over.
- ALU could further dispose assets to raise cash if required.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Leerink Swann Bullish on Insmed (INSM); Raises PT to $22
- Wedbush Expects Positive Results from Insmed (INSM) ARIKAC Trial
Create E-mail Alert Related Categories
Analyst Comments, UpgradesRelated Entities
Deutsche BankLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

